Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Genomic Profiling for Lung Cancer: the Good, the Bad and the Ugly
By Robert A. Nagourney, MD
Genomic profiling has gained popularity in medical oncology. Using NextGen platforms, protein coding regions of human tumors known as exomes can be examined for mutations, amplifications, deletions, splice variants and SNPs. In select tumors...
Future (Cancer) Shock - HSP90 Inhibitors
By Robert A. Nagourney, MD
Two related clinical trials were reported in the last several months describing the use of heat shock protein 90 (HSP90)...
New Diagnostic Test for the Early Detection of Lung Cancer
By Robert A. Nagourney, MD
I was invited to discuss a new diagnostic test for the early detection of lung cancer by Gerri Willis of Fox Business News’...
The Changing Landscape in Non-small Cell Lung Cancer (NSCLC)
By Robert A. Nagourney, MD
In October 2012, we published a study of patients with metastatic NSCLC whose treatment was guided by ourEVA-PCD laboratory...
What is Meaningful Improvement in Lung Cancer? A Look at NSCLC Data
By Robert A. Nagourney, MD
When asked to define what constituted pornography in his 1964 Supreme Court decision (Jacobellis versus Ohio 1964) Justice...
Stage IV NSCLC Patient From the VA Outlives Hospice
By Robert A. Nagourney, MD
For those of you who have read my book Outliving Cancer you will recognize the chapter entitled “Outliving Hospice.” It is the...
Stand Up to Cancer Research! The Downside to Clinical Trials.
By Robert A. Nagourney, MD
As the practice of medicine has moved from a profession to an industrial undertaking, this most human of experiences has fallen...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.